Ability Pharmaceuticals announces regulatory milestones for ABTL0812 in pediatric cancer neuroblastoma

by AbilityPharma

Ability Pharmaceuticals today announced that it has received from the U.S. Food and Drug Administration (FDA), orphan-drug designation (ODD) for ABTL0812, its PI3K/Akt/mTOR pathway inhibitor, for the ...

Read more
Subscribe to Directory
Write an Article

Recent News

¿Por qué no es recomendable llevar la ...

La mejor actitud que podemos adoptar es la de trat...

Exposure to Heat and Cold During Pregnan...

The research team observed changes in head circumf...

Using mobile RNAs to improve Nitrogen a...

AtCDF3 gene induced greater production of sugars a...

Highlight

Eosinófilos. ¿Qué significa tener val...

by Labo'Life

​En nuestro post hablamos sobre este interesante tipo de célula del...

Heat Exposure During Pregnancy and Infan...

by ISGlobal - Instituto de Salud Global de Barcelona

New study finds an association between higher temperatures early in li...

Photos Stream